Potestio Luca, Scalvenzi Massimiliano, Lallas Aimilios, Martora Fabrizio, Guerriero Luigi, Fornaro Luigi, Marano Laura, Villani Alessia
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80138 Naples, Italy.
First Department of Dermatology, School of Medicine, Faculty of Health Sciences, Aristotle University, 541 24 Thessaloniki, Greece.
Cancers (Basel). 2024 Apr 29;16(9):1732. doi: 10.3390/cancers16091732.
Non-melanoma skin cancer includes several types of cutaneous tumors, with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) as the commonest. Among the available therapeutic options, surgical excision is the mainstay of treatment for both tumors. However, tumor features and patients' comorbidities may limit the use of these techniques, making the treatment challenging. As regards BCC, even if hedgehog inhibitors revolutionized the therapeutic scenario, there are still patients unresponsive or intolerant to these drugs. In this context, cemiplimab has been approved as second-line treatment. As regards SCC, cemiplimab was the first systemic therapy approved. The objective of this manuscript was to investigate the efficacy and safety of cemiplimab for the management of BCC and cSCC. Cemiplimab has a durable and significant effect for the management of BCC and CSCC, with a favorable safety profile. Different specialists including oncologists, radiologists, dermatologists, and surgeons are required to guarantee an integrated approach, leading to the best management of patients. Moreover, the collaboration among specialists will allow them to best manage the TEAEs, reducing the risk of treatment suspension or discontinuation. Certainly, ongoing studies and more and more emerging real-world evidence, will allow us to better characterize the role of cemiplimab for the management of advanced non-melanoma skin cancer.
非黑色素瘤皮肤癌包括几种皮肤肿瘤类型，其中基底细胞癌（BCC）和皮肤鳞状细胞癌（cSCC）最为常见。在现有的治疗选择中，手术切除是这两种肿瘤的主要治疗方法。然而，肿瘤特征和患者的合并症可能会限制这些技术的应用，使治疗具有挑战性。对于BCC，即使刺猬抑制剂彻底改变了治疗方案，但仍有患者对这些药物无反应或不耐受。在这种情况下，西米普利单抗已被批准作为二线治疗药物。对于SCC，西米普利单抗是首个被批准的全身治疗药物。本手稿的目的是研究西米普利单抗治疗BCC和cSCC的疗效和安全性。西米普利单抗对BCC和CSCC的治疗具有持久且显著的效果，安全性良好。需要包括肿瘤学家、放射科医生、皮肤科医生和外科医生在内的不同专家来保证综合治疗方法，从而实现对患者的最佳管理。此外，专家之间的合作将使他们能够更好地管理治疗中出现的不良事件，降低治疗中断或停止的风险。当然，正在进行的研究以及越来越多新出现的真实世界证据，将使我们能够更好地描绘西米普利单抗在晚期非黑色素瘤皮肤癌治疗中的作用。
